During 2015, marginal revenues were generated from external customers. All revenues generated relate to sales of C-Cathez to a limited number of customers located in the US.
|
€‘000 |
For the year ended December 31, 2015 | |||||||||||||||
| Cardiology | Immuno- oncology |
Corporate | Group Total | |||||||||||||
|
Revenue |
3 | 3 | ||||||||||||||
|
Cost of Sales |
(1 | ) | (1 | ) | ||||||||||||
|
Gross Profit |
2 | — | — | 2 | ||||||||||||
|
Research & Development expenses |
(20,634 | ) | (2,132 | ) | (22,766 | ) | ||||||||||
|
General & Administrative expenses |
— | — | (7,230 | ) | (7,230 | ) | ||||||||||
|
Other operating Income & Charges |
218 | 104 | 322 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Operating Profit (Loss) |
(20,414 | ) | (2,028 | ) | (7,230 | ) | (29,672 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net Financial Charges |
— | — | 306 | 306 | ||||||||||||
|
Share of Loss of investments accounted for using the equity method |
— | — | 252 | 252 | ||||||||||||
|
Profit (Loss) before taxes |
(20,414 | ) | (2,028 | ) | (6,672 | ) | (29,114 | ) | ||||||||
|
Income Taxes |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Profit (Loss) for the year 2015 |
(20,414 | ) | (2,028 | ) | (6,672 | )) | (29.114 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
In August 2016, the Group has received a non-refundable upfront payment as a result of the ONO agreement. This upfront payment has been fully recognised upon receipt as there are no performance obligations nor subsequent deliverables associated to the payment. The non-refundable upfront payment was rather received as a consideration for the sale of licence to ONO. In 2016, the total revenue generated through sales of C-Cathez was € 0.1 million.
| €‘000 | For the year ended December 31, 2016 | |||||||||||||||
| Cardiology | Immuno- oncology |
Corporate | Group Total | |||||||||||||
|
Revenue |
84 | 8,440 | 8,523 | |||||||||||||
|
Cost of Sales |
(53 | ) | (53 | ) | ||||||||||||
|
Gross Profit |
31 | 8,440 | — | 8,471 | ||||||||||||
|
Research & Development expenses |
(12,704 | ) | (14,971 | ) | (27,675 | ) | ||||||||||
|
General & Administrative expenses |
— | — | (9,744 | ) | (9,744 | ) | ||||||||||
|
Other operating Income & Charges |
1,540 | 1,800 | 3,340 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Operating Profit (Loss) |
(11,133 | ) | (4,731 | ) | (9,744 | ) | (25,609 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net Financial Charges |
— | — | 1,997 | 1,997 | ||||||||||||
|
Profit (Loss) before taxes |
(11,133 | ) | (4,731 | ) | (7,747 | ) | (23,612 | ) | ||||||||
|
Income Taxes |
— | — | 6 | 6 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Profit (Loss) for the year 2016 |
(11,133 | ) | (4,731 | ) | (7,742 | ) | (23,606 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
In 2017, there were some important one-time non-recurrent items impacting significantly the consolidated income statement. The Board decided to isolate these non-recurrent items in the presentation of the consolidated income statement.
|
€‘000 |
For the year ended December 31, 2017 | |||||||||||||||
| Cardiology | Immuno- oncology |
Corporate | Group Total | |||||||||||||
|
Revenues |
35 | 3,505 | 3,540 | |||||||||||||
|
Cost of Sales |
(515 | ) | (515 | ) | ||||||||||||
|
Gross Profit |
35 | 2,990 | — | 3,025 | ||||||||||||
|
Research & Development expenses |
(2,881 | ) | (20,027 | ) | — | (22,908 | ) | |||||||||
|
General & Administrative expenses |
— | — | (9,310 | ) | (9,310 | ) | ||||||||||
|
Other operating Income & Charges |
1,070 | 151 | 1,370 | 2,590 | ||||||||||||
|
Non-recurring operating (expenses)/income |
(1,932 | ) | — | (24,341 | ) | (26,273 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Operating Profit (Loss)—EBIT |
(3,708 | ) | (16,886 | ) | (32,281 | ) | (52,876 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net Financial Charges |
— | — | (3,518 | ) | (3,518 | ) | ||||||||||
|
Profit (Loss) before taxes |
(3,708 | ) | (16,886 | ) | (35,799 | ) | (56,396 | ) | ||||||||
|
Income Taxes |
— | — | 1 | 1 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Profit (Loss) for the year 2017 |
(3,708 | ) | (16,886 | ) | (35,798 | ) | (56,395 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||